Bajraktari Gani, Rexhaj Zarife, Elezi Shpend, Zhubi-Bakija Fjolla, Bajraktari Artan, Bytyçi Ibadete, Batalli Arlind, Henein Michael Y
Department of Public Health and Clinical Medicine, Umeå University, 90187 Umeå, Sweden.
Clinic of Cardiology, University Clinical Centre of Kosova, 10000 Prishtina, Kosovo.
J Clin Med. 2021 May 17;10(10):2163. doi: 10.3390/jcm10102163.
In patients undergoing diagnostic coronary angiography (CA) and percutaneous coronary interventions (PCI), the benefits associated with radial access compared with the femoral access approach remain controversial. The aim of this meta-analysis was to compare the short-term evidence-based clinical outcome of the two approaches.
The PubMed, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases were searched for randomized controlled trials (RCTs) comparing radial versus femoral access for CA and PCI. We identified 34 RCTs with 29,352 patients who underwent CA and/or PCI and compared 14,819 patients randomized for radial access with 14,533 who underwent procedures using femoral access. The follow-up period for clinical outcome was 30 days in all studies. Data were pooled by meta-analysis using a fixed-effect or a random-effect model, as appropriate. Risk ratios (RRs) were used for efficacy and safety outcomes.
Compared with femoral access, the radial access was associated with significantly lower risk for all-cause mortality (RR: 0.74; 95% confidence interval (CI): 0.61 to 0.88; = 0.001), major bleeding (RR: 0.53; 95% CI:0.43 to 0.65; ˂ 0.00001), major adverse cardiovascular events (MACE)(RR: 0.82; 95% CI: 0.74 to 0.91; = 0.0002), and major vascular complications (RR: 0.37; 95% CI: 0.29 to 0.48; ˂ 0.00001). These results were consistent irrespective of the clinical presentation of ACS or STEMI.
Radial access in patients undergoing CA with or without PCI is associated with lower mortality, MACE, major bleeding and vascular complications, irrespective of clinical presentation, ACS or STEMI, compared with femoral access.
在接受诊断性冠状动脉造影(CA)和经皮冠状动脉介入治疗(PCI)的患者中,桡动脉入路与股动脉入路相比的益处仍存在争议。本荟萃分析的目的是比较两种入路的短期循证临床结局。
检索PubMed、Embase、Cochrane对照试验中央注册库和ClinicalTrials.gov数据库,以查找比较CA和PCI中桡动脉与股动脉入路的随机对照试验(RCT)。我们确定了34项RCT,共29352例接受CA和/或PCI的患者,并将14819例随机接受桡动脉入路的患者与14533例接受股动脉入路手术的患者进行比较。所有研究的临床结局随访期均为30天。根据情况,使用固定效应或随机效应模型通过荟萃分析汇总数据。风险比(RR)用于疗效和安全性结局。
与股动脉入路相比,桡动脉入路与全因死亡率(RR:0.74;95%置信区间(CI):0.61至0.88;P = 0.001)、大出血(RR:0.53;95%CI:0.43至0.65;P ˂ 0.00001)、主要不良心血管事件(MACE)(RR:0.82;95%CI:0.74至0.91;P = 0.0002)和主要血管并发症(RR:0.37;95%CI:0.29至0.48;P ˂ 0.00001)的风险显著降低相关。无论急性冠状动脉综合征(ACS)或ST段抬高型心肌梗死(STEMI)的临床表现如何,这些结果都是一致的。
无论临床表现为ACS或STEMI,接受或未接受PCI的CA患者采用桡动脉入路与股动脉入路相比,死亡率、MACE、大出血和血管并发症更低。